Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9BWG6
UPID:
SCNM1_HUMAN
Alternative names:
-
Alternative UPACC:
Q9BWG6; B4DWR1; Q5JR74
Background:
Sodium channel modifier 1 plays a crucial role in the minor spliceosome, essential for the splicing of U12-type introns in pre-mRNAs. It also influences primary cilia length and Hedgehog signaling, pivotal for cellular communication and development.
Therapeutic significance:
Linked to Orofaciodigital syndrome 19, a genetic disorder marked by oral, facial, and digital anomalies, Sodium channel modifier 1's genetic variations suggest a pathway for therapeutic intervention. Understanding its role could unveil new therapeutic strategies.